Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Novo Nordisk ( (NVO) ) has issued an update.
On January 27, 2025, Novo Nordisk announced the ongoing execution of its share repurchase programme, which was initiated on November 11, 2024. This programme is part of a larger strategy to repurchase up to DKK 20 billion worth of shares over a 12-month period starting February 6, 2024. As of January 24, 2025, the company has repurchased 24,221,173 B shares, with a total transaction value of DKK 19,645,420,230. This strategic move is likely aimed at enhancing shareholder value and solidifying Novo Nordisk’s position in the market.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The company focuses on driving change to combat serious chronic diseases, particularly in the realm of diabetes, through scientific innovation and expanded access to its medications. Novo Nordisk employs around 72,000 people across 80 countries and markets its products in approximately 170 countries. Its B shares are listed on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
YTD Price Performance: 0.51%
Average Trading Volume: 7,907,214
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $387B
For a thorough assessment of NVO stock, go to TipRanks’ Stock Analysis page.
